Sugi Predict

Sugi Predict / Compounds / SCHEMBL202628

SCHEMBL202628

SCHEMBL202628

COCCOc1cccc(C(N)=O)c1

nearest known ligand 0.65

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ PARP1 P09874 1/20 0.65
▸ CHEK2 O96017 2/20 0.57
▸ CHEK1 O14757 1/20 0.57
▸ PARP10 Q53GL7 2/20 0.54
▸ KMT2A Q03164 1/20 0.54
▸ PRSS1 P07477 8/20 0.53
▸ TNKS O95271 1/20 0.53
▸ PARP15 Q460N3 1/20 0.53
▸ PARP14 Q460N5 1/20 0.53
▸ TNKS2 Q9H2K2 1/20 0.53
▸ PARP2 Q9UGN5 1/20 0.53
▸ SMPD1 P17405 2/20 0.50
▸ F10 P00742 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30938023 1.00 PARP1 (0.65) PARP1CHEK2CHEK1PARP10KMT2A
SCHEMBL30432308 0.95 PARP1 (0.59) PARP1CHEK2CHEK1PARP10KMT2A
SCHEMBL28294885 0.87 L3MBTL1 (0.57) KMT2ASMPD1
SCHEMBL4017067 0.86 SMPD1 (0.56) KMT2ASMPD1F10
SCHEMBL1665037 0.85 KMT2A (0.55) CHEK2CHEK1KMT2APRSS1SMPD1
SCHEMBL1665041 0.85 KMT2A (0.73) KMT2ASMPD1
SCHEMBL28124115 0.85 PARP1 (0.67) PARP1PARP10KMT2APRSS1TNKS
SCHEMBL30517635 0.85 KMT2A (0.73) KMT2ASMPD1
SCHEMBL10989423 0.85 MAOB (0.60) KMT2A
SCHEMBL201524 0.85 KMT2A (0.73) PARP1PARP10KMT2APRSS1TNKS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102008459-B Antibacterial agents BIOTA SCIENT MAN 2013-05-29 — — CN claimed
US-20260014133-A1 SUBSTITUTED 3-(l-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE/2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE-l,3-DIONE ANALOGS AS MODULATORS OF CEREBLON PROTEIN ST JUDES CHIDRENS RES HOSPITAL INC (US) 2026-01-15 — — US disclosed
US-20250179008-A1 ANTIBACTERIAL AGENTS TAXIS PHARMACEUTICALS, INC. (US) 2025-06-05 — — US disclosed
US-11866431-B2 Bicyclic compounds VIVACE THERAPEUTICS, INC. (US) 2024-01-09 — — US disclosed
US-20230061429-A1 BICYCLIC COMPOUNDS VIVACE THERAPEUTICS, INC. 2023-03-02 — — US disclosed
EP-3324977-B1 BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS ENANTA PHARM INC (US) 2022-07-13 — — EP disclosed
EP-3877356-A1 BICYCLIC COMPOUNDS Vivace Therapeutics, Inc. (US) 2021-09-15 — — EP disclosed
CN-113302175-A Bicyclic compounds 维瓦斯治疗公司 2021-08-24 — — CN disclosed
US-20150191420-A1 ANTIBACTERIAL AGENTS TAXIS PHARMACEUTICALS, INC. 2015-07-09 — — US disclosed
US-20150191420-A1 ANTIBACTERIAL AGENTS TAXIS PHARMACEUTICALS, INC. 2015-07-09 — — US disclosed
CN-102008459-A Antibacterial agents PROLYSIS LTD 2011-04-13 — — CN disclosed
US-20100173933-A1 ANTIBACTERIAL AGENTS PROLYSIS LTD (GB) 2010-07-08 — — US disclosed
US-20100173933-A1 ANTIBACTERIAL AGENTS PROLYSIS LTD (GB) 2010-07-08 — — US disclosed
US-20100173933-A1 ANTIBACTERIAL AGENTS PROLYSIS LTD (GB) 2010-07-08 — — US disclosed
US-20090252013-A1 HYDRAZIDE CHELATE COMPLEX COMPOUND, OPTICAL RECORDING MEDIUM USING THE COMPOUND AND RECORDING METHOD THEREOF MITSUBISHI CHEMICAL CORPORATION (JP) 2009-10-08 — — US disclosed
US-20090252013-A1 HYDRAZIDE CHELATE COMPLEX COMPOUND, OPTICAL RECORDING MEDIUM USING THE COMPOUND AND RECORDING METHOD THEREOF MITSUBISHI CHEMICAL CORPORATION (JP) 2009-10-08 — — US disclosed
CN-101404989-A Antibacterial agent PROLYSIS LTD (GB) 2009-04-08 — — CN disclosed
WO-2007107758-A1 ANTIBACTERIAL AGENTS PROLYSIS LTD (GB) 2007-09-27 — — WO disclosed
US-5215738-A Used for destroying hypoxic tumor cells SRI INTERNATIONAL (US) 1993-06-01 — — US disclosed
WO-1986006628-A1 BENZAMIDE AND NICOTINAMIDE RADIOSENSITIZERS SRI INTERNATIONAL (US) 1986-11-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11866431-B2 Bicyclic compounds YAP1, MYC, TEAD2 PARP1 360/4885CHEK2 158/4885CHEK1 295/4885
US-20150191420-A1 ANTIBACTERIAL AGENTS ALK, ARG1, ROS1 PARP1 1040/4885CHEK2 2557/4885CHEK1 2649/4885
US-20260014133-A1 SUBSTITUTED 3-(l-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE/2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE-l,3-DIONE ANALOGS AS MODULATORS OF CEREBLON PROTEIN CRBN, CDR2, CLNS1A PARP1 3282/4885CHEK2 792/4885CHEK1 1237/4885
US-20230061429-A1 BICYCLIC COMPOUNDS YAP1, MYC, TEAD2 PARP1 360/4885CHEK2 158/4885CHEK1 295/4885
US-20090252013-A1 HYDRAZIDE CHELATE COMPLEX COMPOUND, OPTICAL RECORDING MEDIUM USING THE COMPOUND AND RECORDING METHOD THEREOF KCNN2, KCNH2, KCNN1 PARP1 2657/4885CHEK2 4492/4885CHEK1 4450/4885
US-20250179008-A1 ANTIBACTERIAL AGENTS ALK, ROS1, NOX1 PARP1 1034/4885CHEK2 2107/4885CHEK1 1640/4885
US-20100173933-A1 ANTIBACTERIAL AGENTS ALK, ROS1, NOX1 PARP1 1034/4885CHEK2 2107/4885CHEK1 1640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.